Albemarle completes sale of Ketjen stake to KPS for about $547 million
On March 2, 2026, Albemarle completed the sale of its 51% interest in Ketjen to an affiliate of KPS Capital Partners, and expects to receive about $547 million in cash, including $22 million of cash held in Ketjen. Including the earlier Eurecat joint venture sale, combined pre-tax proceeds total $670 million, which Albemarle expects to use for debt reduction and general corporate purposes. The same day, Albemarle also announced tender offers for up to $500 million of its senior notes and the redemption of $650 million of 2027 notes.
Key points
- Ketjen sale completed March 2, 2026; expected cash of about $547 million, including $22 million of cash held in Ketjen
- Combined pre-tax proceeds with the Eurecat sale, completed January 2026, total $670 million
- Albemarle keeps a 49% stake in Ketjen and 100% of Performance Catalyst Solutions
- Tender offers capped at $500 million expire March 30, 2026; $650 million of 4.650% 2027 notes to be redeemed March 12, 2026
The filing
Written by AI on Nov 8, 2026, 1:12 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on March 06, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.